- Home
- CRVS vs QUAD Comparison
CRVS vs QUAD Comparison
Compare CRVS & QUAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- QUAD
- Stock Information
- Founded
- CRVS 2014
- QUAD 1971
- Country
- CRVS United States
- QUAD United States
- Employees
- CRVS N/A
- QUAD N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- QUAD Publishing
- Sector
- CRVS Health Care
- QUAD Consumer Discretionary
- Exchange
- CRVS Nasdaq
- QUAD Nasdaq
- Market Cap
- CRVS 305.4M
- QUAD 304.4M
- IPO Year
- CRVS 2016
- QUAD 2010
- Fundamental
- Price
- CRVS $5.75
- QUAD $6.66
- Analyst Decision
- CRVS Strong Buy
- QUAD Strong Buy
- Analyst Count
- CRVS 4
- QUAD 2
- Target Price
- CRVS $15.00
- QUAD $9.30
- AVG Volume (30 Days)
- CRVS 518.7K
- QUAD 339.1K
- Earning Date
- CRVS 08-07-2025
- QUAD 10-27-2025
- Dividend Yield
- CRVS N/A
- QUAD 4.50%
- EPS Growth
- CRVS N/A
- QUAD N/A
- EPS
- CRVS N/A
- QUAD N/A
- Revenue
- CRVS N/A
- QUAD $2,584,500,000.00
- Revenue This Year
- CRVS N/A
- QUAD N/A
- Revenue Next Year
- CRVS N/A
- QUAD N/A
- P/E Ratio
- CRVS N/A
- QUAD N/A
- Revenue Growth
- CRVS N/A
- QUAD N/A
- 52 Week Low
- CRVS $2.54
- QUAD $4.13
- 52 Week High
- CRVS $10.00
- QUAD $9.13
- Technical
- Relative Strength Index (RSI)
- CRVS 65.10
- QUAD 60.90
- Support Level
- CRVS $5.28
- QUAD $6.35
- Resistance Level
- CRVS $5.64
- QUAD $6.62
- Average True Range (ATR)
- CRVS 0.30
- QUAD 0.25
- MACD
- CRVS 0.03
- QUAD 0.02
- Stochastic Oscillator
- CRVS 77.70
- QUAD 74.21
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About QUAD Quad Graphics Inc
Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America and others countries. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market..